Tough year takes its toll on B-MS shares and outlook

26 January 2017

US pharma major Bristol-Myers Squibb (NYSE: BMY) might have been able to point to a 17% increase in its 2016 sales compared to 2015, but it share price and outlook for 2017 tell a different story of the year it has had.

Its key immuno-oncology drug Opdivo (nivolumab) was a massive seller but it has had a tough time in the race against lead competitor Keytruda (pembrolizumab), marketed by US pharma giant Merck & Co (NYSE: MRK), in particular with the news that B-MS’ treatment had failed to meet the main goal of a critical study exploring its first-line use in advanced lung cancer patients.

This month’s news that B-MS had decided not to pursue an accelerated regulatory pathway for Opdivo in combination with Yervoy (ipilimumab) in the same indication was a further blow, increasing the need further for B-MS to accentuate the positive as the annual results were published on Thursday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK